| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERV.13.30 |
| P698 | PubMed publication ID | 23659299 |
| P50 | author | Scott A Halperin | Q65555423 |
| Shelley Deeks | Q106292084 | ||
| David W Scheifele | Q44627666 | ||
| Julie Bettinger | Q47805084 | ||
| P2093 | author name string | Raymond Tsang | |
| P2860 | cites work | Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms | Q24685491 |
| Meningococcal carriage and disease--population biology and evolution | Q28246008 | ||
| Neisseria meningitidis: an overview of the carriage state | Q28277386 | ||
| International Circumpolar Surveillance, an Arctic network for the surveillance of infectious diseases | Q30229114 | ||
| Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease | Q30818836 | ||
| Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis | Q48761076 | ||
| The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. | Q50603154 | ||
| Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. | Q51853249 | ||
| Relative incidence estimation from case series for vaccine safety evaluation. | Q52348685 | ||
| Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. | Q53669435 | ||
| Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study | Q56706209 | ||
| Lack of Association between Group B Meningococcal Disease and Autoimmune Disease | Q57230938 | ||
| Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity | Q57531180 | ||
| A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial | Q57588792 | ||
| Antigenic Shift and Increased Incidence of Meningococcal Disease | Q57707003 | ||
| The Disease Burden of Invasive Meningococcal Serogroup B Disease in Canada | Q57768738 | ||
| The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology | Q33610843 | ||
| Review of meningococcal group B vaccines | Q33646965 | ||
| Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005 | Q33729202 | ||
| Virulence evolution of the human pathogen Neisseria meningitidis by recombination in the core and accessory genome | Q33889347 | ||
| Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? | Q33956691 | ||
| Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination | Q34168120 | ||
| Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines | Q34320259 | ||
| Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. | Q34396428 | ||
| The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains | Q34500581 | ||
| More vaccines for children? Parents' views | Q34699207 | ||
| Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningoc | Q34739055 | ||
| Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis | Q34836342 | ||
| Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). | Q35073151 | ||
| Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections | Q35290278 | ||
| Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2. | Q35518459 | ||
| Extensive genomic variation within clonal complexes of Neisseria meningitidis. | Q35623008 | ||
| Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. | Q35942903 | ||
| A universal vaccine for serogroup B meningococcus | Q36101910 | ||
| Parents' experiences of living through their child's suffering from and surviving severe meningococcal disease | Q36102066 | ||
| Capsular switching in invasive Neisseria meningitidis, Brazil(1). | Q36148009 | ||
| Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci | Q36981703 | ||
| Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. | Q37524027 | ||
| Genetic shifts ofNeisseria meningitidisserogroup B antigens and the quest for a broadly cross-protective vaccine | Q37798011 | ||
| The changing and dynamic epidemiology of meningococcal disease | Q37969481 | ||
| A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. | Q38467225 | ||
| Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. | Q38476215 | ||
| Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial | Q39474265 | ||
| Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence | Q39667409 | ||
| Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial | Q40287703 | ||
| Increase in serogroup C meningococcal disease in Canada is associated with antigenic changes in the protein antigens of the ET-15 clone of Neisseria meningitidis | Q43543134 | ||
| Serogroup C meningococcal outbreaks in the United States. An emerging threat | Q44582415 | ||
| Global epidemiology of meningococcal disease. | Q44677055 | ||
| Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland | Q45115223 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meningococcal disease | Q890785 |
| P304 | page(s) | 505-517 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Controlling serogroup B invasive meningococcal disease: the Canadian perspective | |
| P478 | volume | 12 |
| Q37471668 | A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program |
| Q38674381 | Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease. |
| Q92309241 | Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story |
| Q38286082 | Evolving meningococcal immunization strategies |
| Q37309237 | Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement |
| Q38603389 | Global incidence of serogroup B invasive meningococcal disease: a systematic review |
| Q26782285 | Meningococcal B Vaccination (4CMenB) in Infants and Toddlers |
| Q30249575 | Meningococcal B vaccination: real-world experience and future perspectives. |
| Q100511663 | Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates |
| Q38183156 | Neisseria meningitidis B vaccines: recent advances and possible immunization policies. |
| Q37690815 | New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers |
| Q34290793 | Routine vaccination against MenB: considerations for implementation |
Search more.